Register free for our breaking news email alerts with analysis and cutting edge commentary from our award winning team. Registration only takes a minute.
Please see terms and conditions for restrictions on use of Citywire's Fund Manager database.

This Fund Manager Rating is based on the Citywire Long Only ratings methodology

Citywire Ratings are rewarded for risk adjusted outperformance of benchmarks we select independently More information on how Ratings are calculated

David Pinniger

David Pinniger

Showing manager performance in Switzerland View performance globally

About David Pinniger

David Pinniger joined Polar Capital in 2013 and is manager of the Polar Capital Biotechnology Fund. Prior to joining Polar Capital, he worked at SV Life Sciences, Abingworth and Morgan Stanley. David holds a first class honours degree in Human Sciences from the University of Oxford and is a CFA charterholder.

Are you David Pinniger?

Citywire Rating: AAA rated


  • NRated AA in Nov 2016
  • DRated AAA in Dec 2016


  • JRated AAA in Jan 2017
  • FRated AAA in Feb 2017
  • MRated AAA in Mar 2017
  • ARated AAA in Apr 2017
  • MRated AAA in May 2017
  • JRated AAA in Jun 2017
  • JRated AAA in Jul 2017
  • ARated AAA in Aug 2017
  • SRated AAA in Sep 2017
  • ORated AAA in Oct 2017
  • NRated AAA in Nov 2017
  • DRated AAA in Dec 2017


  • JRated AAA in Jan 2018
  • FRated AAA in Feb 2018
  • MRated AAA in Mar 2018
  • ARated AAA in Apr 2018
  • MRated AAA in May 2018
  • JRated AAA in Jun 2018


Equity - Biotechnology
over : 31/05/2017 - 31/05/2018

Total Return

Month by Month Performance

Quarterly Performance

to 31/03/2018 Annual Q1 Q2 Q3 Q4
2018 4.5%
2017 24.8% 12.8% 0.4% 10.0% 0.2%
2016 -6.5% -22.4% 4.4% 12.9% 2.2%
2015 13.2% 11.1% 3.7% -12.7% 12.6%
2014 64.8% 17.5% 5.2% 13.9% 17.1%

Related News

Polar Capital: biotech set for M&A surge in post-election rally

Citywire AA-rated David Pinniger discusses biotech's place in 2017 and reveals his favourite market players

Healthcare industry fighting fit after Trump win

From pricing pressures to Obamacare overhauls, leading managers reveal what the election impact for healthcare could be.

Polar Capital's Pinniger on 'phenomenal' biotech bargains

An immense innovation cycle is underway and beaten up small companies are at the heart of it, says biotech veteran David Pinniger.

Citywire Switzerland 2016: the key event for Swiss fund buyers

Gstaad Palace set to once again play host to over 100 leading Swiss fund selectors, as well as prominent guest speakers and top fund managers.

Squashing superbugs: top healthcare managers on the challenges ahead

With the global demand for drugs to treat bacterial diseases growing, sector specialists discuss what hurdles still need to be overcome.

Citywire Geneva Fund Selector Forum 2015

Selectors and investment professionals are invited to join their peers and a line-up of leading fund managers at the annual half-day event.

Taking new medicine: how to tap biotech’s small-cap stand-outs

Polar Capital’s David Pinniger is overweighting smaller firms in the fast-moving sector as risk appetite increases.

Citywire Discovery Source: Citywire Discovery Performance is for the period shown (month end to month end, bid/bid, gross income reinvested, calculated in the currency and currencies indicated)..Portions of the information contained on this page was derived by Citywire Financial Publishers Ltd using content supplied by Lipper, A Reuters Company.